colforsin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caiafa, I; Capasso, L; Chiosi, E; Illiano, M; Naviglio, S; Salzillo, A; Sapio, L; Spina, A | 1 |
| Ding, HF; Dong, Z; Fang, D; Huang, S; Jing, Q; Li, Y; Su, SB; Wang, W; Zhu, JY | 1 |
2 other study(ies) available for colforsin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition.
Topics: Cell Line, Tumor; Colforsin; Cyclic AMP-Dependent Protein Kinases; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms | 2018 |
Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition.
Topics: Animals; Cell Line, Tumor; Colforsin; Computational Biology; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Female; Humans; Mice; Mice, Inbred BALB C; Multidrug Resistance-Associated Proteins; Probenecid; Rolipram; Triple Negative Breast Neoplasms | 2016 |